QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

$5.69
-0.04 (-0.70%)
(As of 02/22/2024 ET)
Today's Range
$5.67
$5.91
50-Day Range
$5.00
$6.21
52-Week Range
$1.24
$6.30
Volume
945,308 shs
Average Volume
1.31 million shs
Market Capitalization
$1.74 billion
P/E Ratio
94.83
Dividend Yield
N/A
Price Target
$5.40

Amneal Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
5.1% Downside
$5.40 Price Target
Short Interest
Healthy
2.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.85mentions of Amneal Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
2.04%
From $0.49 to $0.50 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.38 out of 5 stars

Medical Sector

795th out of 934 stocks

Drug Manufacturers - Specialty & Generic Industry

1st out of 1 stocks


AMRX stock logo

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

AMRX Stock Price History

AMRX Stock News Headlines

Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Amneal to Participate at Upcoming Investor Conference
Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Top 3 Pharma Stocks With Bullish Momentum
Knight Therapeutics Inks License Agreement With Amneal Pharma For IPX203
Amneal Announces Move to Nasdaq
Amneal Pharmaceuticals Q3 Profit Tops Estimates; Revenue Up 14%
See More Headlines
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/05/2023
Today
2/22/2024
Next Earnings (Confirmed)
3/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
Employees
7,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.40
High Stock Price Target
$8.00
Low Stock Price Target
$3.00
Potential Upside/Downside
-6.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-129,990,000.00
Pretax Margin
1.49%

Debt

Sales & Book Value

Annual Sales
$2.21 billion
Cash Flow
$1.42 per share
Book Value
$0.61 per share

Miscellaneous

Free Float
225,126,000
Market Cap
$1.77 billion
Optionable
Optionable
Beta
1.34
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















AMRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amneal Pharmaceuticals stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AMRX shares.
View AMRX analyst ratings
or view top-rated stocks.

What is Amneal Pharmaceuticals' stock price target for 2024?

5 Wall Street research analysts have issued 1 year price objectives for Amneal Pharmaceuticals' shares. Their AMRX share price targets range from $3.00 to $8.00. On average, they predict the company's share price to reach $5.40 in the next year. This suggests that the stock has a possible downside of 5.1%.
View analysts price targets for AMRX
or view top-rated stocks among Wall Street analysts.

How have AMRX shares performed in 2024?

Amneal Pharmaceuticals' stock was trading at $6.07 at the start of the year. Since then, AMRX stock has decreased by 6.3% and is now trading at $5.69.
View the best growth stocks for 2024 here
.

When is Amneal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 1st 2024.
View our AMRX earnings forecast
.

How can I listen to Amneal Pharmaceuticals' earnings call?

Amneal Pharmaceuticals will be holding an earnings conference call on Friday, March 1st at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced its earnings results on Friday, May, 5th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. The business earned $557.54 million during the quarter, compared to analysts' expectations of $555 million. Amneal Pharmaceuticals had a trailing twelve-month return on equity of 109.82% and a net margin of 0.43%. During the same quarter last year, the firm earned $0.10 EPS.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, January, 10th. The company provided EPS guidance of $0.51-0.58 for the period, compared to the consensus EPS estimate of $0.59. The company issued revenue guidance of $2.37-2.42 billion, compared to the consensus revenue estimate of $2.41 billion.

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.45%), Rubric Capital Management LP (2.61%), Dimensional Fund Advisors LP (0.92%), Nantahala Capital Management LLC (0.76%), Nuveen Asset Management LLC (0.64%) and Charles Schwab Investment Management Inc. (0.43%). Insiders that own company stock include Andrew S Boyer, Chirag K Patel, Gautam Patel, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends
.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMRX) was last updated on 2/22/2024 by MarketBeat.com Staff